Loading...
XCNQ
SONA
Market cap24mUSD
Jul 09, Last price  
0.30CAD
1D
7.14%
1Q
0.00%
Jan 2017
900.00%
IPO
76.47%
Name

Sona Nanotech Inc

Chart & Performance

D1W1MN
XCNQ:SONA chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
13.30%
Rev. gr., 5y
%
Revenues
0k
3,674279,735262,62300000000000000000
Net income
-3m
L+20.21%
-248,861-1,112,000-1,485,000-8,336,000-674,000-696,000-4,844,000-584,082-2,021,853-840,048-3,639,850-2,282,222-5,272,000-2,942,000-6,272,000-10,768,000-2,361,000-2,500,000-2,704,000-3,250,345
CFO
-2m
L+0.07%
-172,979-799,599-1,156,865-530,555-385,535-398,797-721,283-386,734-404,941-54,407-277,607-116,287-1,391,441-1,362,799-4,054,643-3,813,340-1,805,403-1,260,455-1,959,710-1,960,994

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.
IPO date
Oct 04, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑102024‑102023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT